Japan’s biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment. Oncology is a pillar for Takeda as it refocuses on core businesses following last year’s $59 billion takeover of Britain’s Shire. The announcement followed a week of investor conferences at home and in the United States intended to show that its drug pipeline is robust enough to fuel continued growth. …read more
Source:: Yahoo Finance
